Archive · 8 Aug 2025
Eli Lilly's Oral Weight-Loss Pill Shows Positive Trial Results
Eli Lilly has developed an oral weight-loss pill called orforglipron.
In trials, people taking the highest dose lost about 12.4% of their weight.
This is about the same as other weight-loss drugs that you can take by mouth or get as a shot.
However, it's not as effective as Lilly's own injectable weight loss drug.
Because it is a pill, it might be easier for people to use compared to weekly injections.
The pill works by mimicking a hormone in the body that helps regulate blood sugar and reduce appetite.
Eli Lilly's orforglipron, an oral weight-loss pill, showed weight loss in trials.
Participants on the highest dose lost an average of 12.4% of their body weight.
Weight loss with orforglipron is similar to both oral and injectable semaglutide.
Orforglipron is less effective than Eli Lilly's injectable drug, tirzepatide.
Being an oral medication, orforglipron may be easier to use than weekly shots.
- Who
- Eli Lilly, participants in the ATTAIN-1 trial.
- What
- Eli Lilly's orforglipron, an oral weight-loss pill, showed weight loss in trials.
- When
- Findings were announced on Thursday.
- Where
- Trials were conducted across the US, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan.
- Why
- The study aimed to evaluate the efficacy of orforglipron for weight loss.
Ease of Use
Weekly Shots
Accessibility
Ease of Use
Oral medication may be more accessible due to ease of use.
Weekly Shots
Weekly injections may be less convenient for some.
- Drug Name
- orforglipron
- Type
- Oral weight-loss pill
- Highest Dose Weight Loss
- 12.4% of body weight
- Trial Duration
- 72 weeks
- Drug Class
- GLP-1 drug
- Trial Participants
- 3,127
